SillaJen Past Earnings Performance

Past criteria checks 0/6

SillaJen has been growing earnings at an average annual rate of 39.1%, while the Biotechs industry saw earnings growing at 3.8% annually. Revenues have been declining at an average rate of 12.4% per year.

Key information

39.1%

Earnings growth rate

49.1%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate-12.4%
Return on equity-18.6%
Net Margin-2,097.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Is SillaJen (KOSDAQ:215600) Using Too Much Debt?

Nov 04
Is SillaJen (KOSDAQ:215600) Using Too Much Debt?

Is SillaJen (KOSDAQ:215600) A Risky Investment?

Jul 05
Is SillaJen (KOSDAQ:215600) A Risky Investment?

Does SillaJen (KOSDAQ:215600) Have A Healthy Balance Sheet?

Mar 12
Does SillaJen (KOSDAQ:215600) Have A Healthy Balance Sheet?

Revenue & Expenses Breakdown

How SillaJen makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A215600 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,230-25,79522,9060
30 Jun 241,657-23,26521,5770
31 Mar 243,445-21,90622,8390
31 Dec 233,940-20,36921,7830
30 Sep 236,091-21,81524,9760
30 Jun 236,737-22,54725,8550
31 Mar 235,277-22,17223,1710
31 Dec 225,013-24,59324,7320
30 Sep 224,052-24,36027,0000
30 Jun 221,688-23,35923,0770
31 Mar 22555-16,76720,7630
31 Dec 21254-15,65619,4930
30 Sep 211,032-13,02716,8250
30 Jun 211,175-22,53620,3770
31 Mar 211,700-42,09928,4860
31 Dec 201,670-47,82534,6030
30 Sep 201,742-54,74842,9600
30 Jun 202,291-55,70852,6540
31 Mar 207,703-108,42258,1860
31 Dec 199,069-113,20064,2170
30 Sep 199,351-112,92861,3930
30 Jun 1910,962-114,64463,0860
31 Mar 197,093-57,46463,6990
31 Dec 187,712-56,23663,4520
30 Sep 188,771-61,57565,5750
30 Jun 187,543-53,95457,3300
31 Mar 187,315-59,41658,7430
31 Dec 176,865-57,02153,7570
30 Sep 175,690-79,99255,6970
30 Jun 176,236-84,85757,8120
31 Mar 175,568-77,09351,0080
31 Dec 165,292-74,03848,4360
30 Sep 165,806-52,00341,8420
30 Jun 164,065-47,38734,8060
31 Mar 163,126-51,70326,5360
31 Dec 151,810-55,85422,2140
30 Sep 151,099-28,73620,0070
30 Jun 151,616-26,48517,7460
31 Mar 152,021-33,50110,0816,174
31 Dec 142,086-2,47814,9490

Quality Earnings: A215600 is currently unprofitable.

Growing Profit Margin: A215600 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A215600 is unprofitable, but has reduced losses over the past 5 years at a rate of 39.1% per year.

Accelerating Growth: Unable to compare A215600's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A215600 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).


Return on Equity

High ROE: A215600 has a negative Return on Equity (-18.59%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 06:58
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

SillaJen, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wan KuNH Investment & Securities Co., Ltd.
Kidal BaeShinhan Investment Corp.